Julie A. Boom
A5040815474- Respiratory viral infections research
- Vaccine Coverage and Hesitancy
- Viral gastroenteritis research and epidemiology
- Influenza Virus Research Studies
- SARS-CoV-2 and COVID-19 Research
- Viral Infections and Immunology Research
- Pneumonia and Respiratory Infections
- Hepatitis Viruses Studies and Epidemiology
- Animal Virus Infections Studies
- COVID-19 Impact on Reproduction
- Misinformation and Its Impacts
- Neonatal Respiratory Health Research
- Pediatric health and respiratory diseases
- Congenital Diaphragmatic Hernia Studies
- Ethics and Legal Issues in Pediatric Healthcare
- COVID-19 Clinical Research Studies
- Bacterial Infections and Vaccines
- Viral Infections and Vectors
- Kawasaki Disease and Coronary Complications
- Virus-based gene therapy research
- Emergency and Acute Care Studies
- Autism Spectrum Disorder Research
- Media Influence and Health
- Cervical Cancer and HPV Research
- Innovations in Medical Education
Texas Children's Hospital
2016-2025
Baylor College of Medicine
2015-2024
University of Colorado Denver
2022-2024
Cincinnati Children's Hospital Medical Center
2020-2024
University of Arizona
2024
Barnes-Jewish Hospital
2024
Children's Hospital of Pittsburgh
2022-2024
Jewish Hospital
2024
Atrium Health Wake Forest Baptist
2024
Hennepin County
2024
Multisystem inflammatory syndrome in children (MIS-C) is a severe postinfectious hyperinflammatory condition, which generally occurs 2-6 weeks after typically mild or asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19 (1-3). In United States, BNT162b2 (Pfizer-BioNTech) vaccine currently authorized for use and adolescents aged 5-15 years under an Emergency Use Authorization fully licensed by Food Drug Administration persons ≥16 (4). Prelicensure randomized trials ≥5...
Spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (omicron) variant, which led to increased U.S. hospitalizations for disease 2019 (Covid-19), generated concern about immune evasion and duration protection from vaccines in children adolescents.Using a case-control, test-negative design, we assessed vaccine effectiveness against laboratory-confirmed Covid-19 leading hospitalization critical (i.e., receipt life support or death). From July 1, 2021, February...
Respiratory syncytial virus (RSV) is a major cause of hospitalized acute respiratory illness (ARI) among young children. With RSV vaccines and immunoprophylaxis agents in clinical development, we sought to update estimates US pediatric hospitalization burden.Children <5 years old for ARI were enrolled through active, prospective, population-based surveillance from November 1, 2015, June 30, 2016, at 7 hospital sites. Clinical information was obtained parent interviews medical records....
Infants younger than 6 months of age are at high risk for complications coronavirus disease 2019 (Covid-19) and not eligible vaccination. Transplacental transfer antibodies against severe acute respiratory syndrome 2 (SARS-CoV-2) after maternal Covid-19 vaccination may confer protection in infants.
COVID-19 vaccination is recommended for persons who are pregnant, breastfeeding, trying to get pregnant now, or might become in the future, protect them from COVID-19.§ Infants at risk life-threatening complications COVID-19, including acute respiratory failure (1). Evidence other vaccine-preventable diseases suggests that maternal immunization can provide protection infants, especially during high-risk first 6 months of life, through passive transplacental antibody transfer (2). Recent...
The increasing incidence of pediatric hospitalizations associated with coronavirus disease 2019 (Covid-19) caused by the B.1.617.2 (delta) variant severe acute respiratory syndrome 2 (SARS-CoV-2) in United States has offered an opportunity to assess real-world effectiveness BNT162b2 messenger RNA vaccine adolescents between 12 and 18 years age.
The New Vaccine Surveillance Network (NVSN) is a prospective, active, population-based surveillance platform that enrolls children with acute respiratory illnesses (ARIs) at seven pediatric medical centers. ARIs are caused by viruses including influenza virus, syncytial virus (RSV), human metapneumovirus (HMPV), parainfluenza (HPIVs), and most recently SARS-CoV-2 (the causes COVID-19), which result in morbidity among infants young (1-6). NVSN estimates the incidence of pathogen-specific...
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for aged <8 months to protect against RSV-associated lower respiratory tract infection during their first RSV season and children 8-19 at increased risk severe disease. phase 3 clinical trials, nirsevimab efficacy with was 81% (95% CI = 62%-90%) through 150 days...
Rhinoviruses and/or enteroviruses, which continued to circulate during the COVID-19 pandemic, are commonly detected in pediatric patients with acute respiratory illness (ARI). Yet detailed characterization of rhinovirus enterovirus detection over time is limited, especially by age group and health care setting.
In the United States, annual influenza vaccination is recommended for all persons aged ≥6 months.Using data from four vaccine effectiveness (VE) networks during 2023-24 season, interim VE was estimated among patients months with acute respiratory illness-associated medical encounters using a test-negative casecontrol study design.Among children and adolescents 6 months-17 years, against influenza-associated outpatient visits ranged 59% to 67% hospitalization 52% 61%.Among adults ≥18 33% 49%...
BACKGROUND Respiratory syncytial virus (RSV) is the leading cause of hospitalization in US infants. Accurate estimates severe RSV disease inform policy decisions for prevention. METHODS We conducted prospective surveillance children &lt;5 years old with acute respiratory illness from 2016 to 2020 at 7 pediatric hospitals. interviewed parents, reviewed medical records, and tested midturbinate nasal ± throat swabs by reverse transcription polymerase chain reaction other viruses. describe...
OBJECTIVE: The goal was to assess the effectiveness of complete (3-dose) or partial (1- 2-dose) immunization with pentavalent rotavirus vaccine (RV5) against acute gastroenteritis (AGE) in US clinical practice. METHODS: A case-control evaluation conducted February through June 2008 at an emergency department Houston, Texas. Case patients AGE (N = 90) were identified testing for fecal specimens obtained from 205 children 15 days 23 months age presenting AGE. Control groups included...
We assessed vaccine effectiveness (VE) for RotaTeq (RV5; 3 doses) and Rotarix (RV1; 2 at reducing rotavirus acute gastroenteritis (AGE) inpatient emergency department (ED) visits in US children.We enrolled children <5 years of age hospitalized or visiting the ED with AGE symptoms from November 2009-June 2010 2010-June 2011 7 medical institutions. Fecal specimens were tested by enzyme immunoassay genotyped. Vaccination among laboratory-confirmed cases was compared rotavirus-negative controls....
A genetic polymorphism affecting FUT2 secretor status in approximately one-quarter of humans European descent affects the expression histo-blood group antigens on mucosal epithelia human respiratory, genitourinary, and digestive tracts. These serve as host receptor sites necessary for attachment infection some pathogens, including norovirus.We investigated whether an association exists between laboratory-confirmed rotavirus infections US children.Multicenter case-control observational study...
Norovirus is a leading cause of acute gastroenteritis (AGE). Noroviruses bind to gut histo-blood group antigens (HBGAs), but only 70%-80% individuals have functional copy the FUT2 ("secretor") gene required for HBGA expression; these are known as "secretors." Susceptibility some noroviruses depends on secretor status, population impact this association not established.From December 2011 November 2012, active AGE surveillance was performed at 6 geographically diverse pediatric sites in United...
Pfizer-BioNTech COVID-19 vaccine is authorized for use in children and adolescents aged 12-15 years licensed by the Food Drug Administration (FDA) persons ≥16 (1). A randomized placebo-controlled trial demonstrated an efficacy of 100% (95% confidence interval [CI] = 75.3%-100%) preventing outpatient (2); however, data among on effectiveness (VE) against real-world settings are limited, especially hospitalized patients. In early September 2021, U.S. pediatric hospitalizations reached highest...
During June 2021, the highly transmissible† B.1.617.2 (Delta) variant of SARS-CoV-2, virus that causes COVID-19, became predominant circulating strain in United States. U.S. pediatric COVID-19-related hospitalizations increased during July-August 2021 following emergence Delta and peaked September 2021.§ As May 12, CDC recommended COVID-19 vaccinations for persons aged ≥12 years,¶ on November 2, were 5-11 years.** To date, clinical signs symptoms, illness course, factors contributing to...
OBJECTIVES Nonpharmaceutical interventions against coronavirus disease 2019 likely have a role in decreasing viral acute respiratory illnesses (ARIs). We aimed to assess the frequency of syncytial virus (RSV) and influenza ARIs before during pandemic. METHODS This study was prospective, multicenter, population-based ARI surveillance, including children seen emergency departments inpatient settings 7 US cities for ARI. Respiratory samples were collected evaluated by molecular testing....
Background Social media platforms such as YouTube are hotbeds for the spread of misinformation about vaccines. Objective The aim this study was to explore how individuals exposed antivaccine on based whether they start their viewing from a keyword-based search or seed videos. Methods Four networks videos recommendations were collected in November 2019. Two created provaccine and keywords resemble goal-oriented browsing. constructed conspiracy expert direct navigation. Video contents network...
Multisystem inflammatory syndrome in children (MIS-C), linked to antecedent severe acute respiratory coronavirus 2 (SARS-CoV-2) infection, is associated with considerable morbidity. Prevention of SARS-CoV-2 infection or disease 2019 (COVID-19) by vaccination might also decrease MIS-C likelihood.In a multicenter, case-control, public health investigation ages 5-18 years hospitalized from 1 July 2021 7 April 2022, we compared the odds being fully vaccinated (2 doses BNT162b2 vaccine ≥28 days...
Background. Using a multicenter, active surveillance network from 2 rotavirus seasons (2012 and 2013), we assessed the vaccine effectiveness of RV5 (RotaTeq) RV1 (Rotarix) vaccines in preventing gastroenteritis hospitalizations emergency department (ED) visits for numerous demographic secular strata. Methods. We enrolled children hospitalized or visiting ED with acute (AGE) 2012 2013 at 7 medical institutions. Stool specimens were tested by enzyme immunoassay genotyped, vaccination histories...
Background. Group A rotaviruses (RVA) are a significant cause of pediatric gastroenteritis worldwide. The New Vaccine Surveillance Network (NVSN) has conducted active surveillance for RVA at hospitals and emergency departments 3–7 geographically diverse sites in the United States since 2006. Methods. Over 6 consecutive years, from 2008 to 2013, 1523 samples NVSN that were tested positive by Rotaclone enzyme immunoassay submitted Centers Disease Control Prevention genotyping. Results. In...